欧洲呼吸学会指南:慢阻肺吸入糖皮质激素的撤药建议
该欧洲呼吸学会指南基于GRADE方法综合证据,针对慢阻肺患者是否应撤除吸入糖皮质激素提出推荐。指南 panel 提出:对无频繁急性加重史者有条件推荐撤药;对血嗜酸性粒细胞≥300个·µL-1者强烈推荐不撤药;撤药时强烈推荐使用一或两种长效支气管扩张剂。
要点
- 无频繁急性加重史的慢阻肺患者,有条件推荐撤除ICS。
- 血嗜酸性粒细胞≥300个·µL-1者,强烈推荐不撤除ICS。
- 撤除ICS时,强烈推荐改用一或两种长效支气管扩张剂。
核心结论
- 对无频繁急性加重史的慢阻肺患者,有条件推荐撤除ICS。
- 对血嗜酸性粒细胞计数≥300个·µL-1的患者,强烈推荐不撤除ICS。
- 若撤除ICS,强烈推荐使用一或两种长效支气管扩张剂治疗。
研究设计与样本
- 该文件为欧洲呼吸学会(ERS)指南,采用GRADE方法对证据进行综合与分级。
- 由具备慢阻肺专业知识和指南方法学专长的委员会讨论证据并制定推荐。
主要发现
- 指南 panel 在权衡利弊、证据质量及可行性后形成三条推荐。
- 有条件推荐意味着利弊平衡存在不确定性,充分知情的患者可能做出不同选择。
关键数值与推荐
- 无频繁急性加重史:有条件推荐撤除ICS。
- 血嗜酸性粒细胞计数≥300个·µL-1:强烈推荐不撤除ICS。
- 撤除ICS时:强烈推荐使用一或两种长效支气管扩张剂。
临床怎么用
- 对无频繁急性加重史者,可与患者讨论撤除ICS。
- 血嗜酸性粒细胞≥300个·µL-1者,不应撤除ICS。
- 撤药后应确保使用一或两种长效支气管扩张剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inhaled corticosteroids (ICS) combined with bronchodilators can reduce the frequency of exacerbations in some patients with chronic obstructive pulmonary disease (COPD). There is evidence, however, that ICS are frequently used in patients where their benefit has not been established. Therefore, there is a need for a personalised approach to the use of ICS in COPD and to consider withdrawal of ICS in patients without a clear indication. This document reports European Respiratory Society recommendations regarding ICS withdrawal in patients with COPD.Comprehensive evidence synthesis was performed to summarise all available evidence relevant to the question: should ICS be withdrawn in patients with COPD? The evidence was appraised using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and the results were summarised in evidence profiles. The evidence synthesis was discussed and recommendations formulated by a committee with expertise in COPD and guideline methodology.After considering the balance of desirable and undesirable consequences, quality of evidence, and feasibility and acceptability of interventions, the guideline panel made: 1) conditional recommendation for the withdrawal of ICS in patients with COPD without a history of frequent exacerbations, 2) strong recommendation not to withdraw ICS in patients with blood eosinophil counts ≥300 eosinophils·µL-1 and 3) strong recommendation to treat with one or two long-acting bronchodilators if ICS are withdrawn.A conditional recommendation indicates that there was uncertainty about the balance of desirable and undesirable consequences of the intervention, and that well-informed patients may make different choices regarding whether to have or not have the specific intervention.
引用
- Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J. 2020. PMID: 32366483. doi:10.1183/13993003.00351-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。